Product Description
YL-90148, a selective uric acid reabsorption inhibitor independently developed by Yingli Pharma for the treatment of gout and asymptomatic hyperuricemia, has been successfully initiated at Shanghai Xuhui District Central Hospital, China.
Mechanisms of Action: URAT1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Shanghai YingLi Pharmaceutical
Company Location: Asia Pacific
Company Founding Year: 2011
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Gout
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20222473 |
CTR20222473 | P3 |
Recruiting |
Gout |
None |
2025-04-29 |
Patient Enrollment|Treatments |